Next Article in Journal
Changes in Iron Metabolism Induced by Anti-Interleukin-6 Receptor Monoclonal Antibody are Associated with an Increased Risk of Infection
Next Article in Special Issue
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Previous Article in Journal
Design and Synthesis of CNS-targeted Flavones and Analogues with Neuroprotective Potential Against H2O2- and Aβ1-42-Induced Toxicity in SH-SY5Y Human Neuroblastoma Cells
Previous Article in Special Issue
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
Review

Psychotropic Drugs for the Management of Chronic Pain and Itch

1
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, pr. Torez 44, St. Petersburg 194223, Russia
2
International Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland
3
Department of Pedagogy and Psychology, Faculty of Postgraduate Education, First Pavlov State Medical University, L’va Tolstogo str. 6-8, St. Petersburg 197022, Russia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2019, 12(2), 99; https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020099
Received: 26 May 2019 / Revised: 19 June 2019 / Accepted: 21 June 2019 / Published: 24 June 2019
(This article belongs to the Collection The Story of Successful Drugs and Recent FDA-Approved Molecules)
Clinical observations have shown that patients with chronic neuropathic pain or itch exhibit symptoms of increased anxiety, depression and cognitive impairment. Such patients need corrective therapy with antidepressants, antipsychotics or anticonvulsants. It is known that some psychotropic drugs are also effective for the treatment of neuropathic pain and pruritus syndromes due to interaction with the secondary molecular targets. Our own clinical studies have identified antipruritic and/or analgesic efficacy of the following compounds: tianeptine (atypical tricyclic antidepressant), citalopram (selective serotonin reuptake inhibitor), mianserin (tetracyclic antidepressant), carbamazepine (anticonvulsant), trazodone (serotonin antagonist and reuptake inhibitor), and chlorprothixene (antipsychotic). Venlafaxine (serotonin-norepinephrine reuptake inhibitor) is known to have an analgesic effect too. The mechanism of such effect of these drugs is not fully understood. Herein we review and correlate the literature data on analgesic/antipruritic activity with pharmacological profile of these compounds. View Full-Text
Keywords: chronic pain; psychotropic drugs; pharmacological profile; animal model; clinical trial chronic pain; psychotropic drugs; pharmacological profile; animal model; clinical trial
Show Figures

Graphical abstract

MDPI and ACS Style

Belinskaia, D.A.; Belinskaia, M.A.; Barygin, O.I.; Vanchakova, N.P.; Shestakova, N.N. Psychotropic Drugs for the Management of Chronic Pain and Itch. Pharmaceuticals 2019, 12, 99. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020099

AMA Style

Belinskaia DA, Belinskaia MA, Barygin OI, Vanchakova NP, Shestakova NN. Psychotropic Drugs for the Management of Chronic Pain and Itch. Pharmaceuticals. 2019; 12(2):99. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020099

Chicago/Turabian Style

Belinskaia, Daria A., Mariia A. Belinskaia, Oleg I. Barygin, Nina P. Vanchakova, and Natalia N. Shestakova 2019. "Psychotropic Drugs for the Management of Chronic Pain and Itch" Pharmaceuticals 12, no. 2: 99. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020099

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop